Instead of cash director fees, Heather Knight receives 57.41 stock units at Waters (WAT).
Waters Corporation director Heather Knight received 57.41 common stock units on September 30, 2026, as part of the company's 1996 Non-Employee Director Deferred Compensation Plan, in lieu of cash director fees. These units are convertible one-for-one into Waters common shares on January 1, 2027. Following this transaction, Knight's direct holdings increased to 1,338 shares.
Stock replaces cash for director fees at Waters (WAT); Wei Jiang receives 57.41 units.
Waters Corp director Wei Jiang received 57.41 common stock units on September 30, 2026, as payment for director fees, replacing cash under the company's 1996 Non-Employee Director Deferred Compensation Plan. These units convert one-for-one into common stock when Jiang's board service concludes. Following this transaction, Jiang's direct position in common stock units totals 3,630.16.
Waters Corp (WAT) Shares Fall 3.1% -- What GF Score of 94 Tells Investors
Waters Corp (WAT) shares recently fell 3.1% to $425.53, trading slightly above its GF Value™ estimate of $417.54, suggesting it's 1.9% overvalued. Despite a strong GF Score™ of 94/100, driven by high growth and momentum ranks, its financial strength is moderate. Insider activity shows net selling, raising concerns for potential investors.
Waters Corp Price Target Raised to $490.00/Share From $440.00 by Guggenheim
Guggenheim has raised its price target for Waters Corp (NYSE:WAT) from $440.00 to $490.00 per share. This updated target suggests a potential upside from the company's previous closing price. The adjustment reflects Guggenheim's revised outlook on Waters Corp's future performance.
Waters Corp Is Maintained at Buy by Guggenheim
Guggenheim has maintained its Buy rating on Waters Corp (NYSE:WAT). Further details regarding the price target or the analyst's rationale were not provided in this snippet.
Waters Corp stock after-hours at EUR 385.10: minus 0.70 percent versus prior close
Waters Corp (ISIN US9418481035) stock traded at EUR 385.10 in after-hours trading on October 1, 2026, at 5:40 p.m. CEST. This represented a decrease of 0.70 percent, or EUR 2.70, compared to its prior close of EUR 387.80 at Lang & Schwarz. The bid and ask prices at Lang & Schwarz were EUR 384.40 and EUR 385.80 respectively.
An earnings call is set for Nov. 3; Waters' replay stays available until at least Dec. 1.
Waters Corporation (NYSE: WAT) has scheduled its third-quarter 2026 financial results conference call for November 3, 2026, at 8:00 a.m. Eastern Time. A live webcast will be accessible on Waters' Investor Relations website, with a replay available until at least December 1, 2026. The company is a global leader in life sciences and diagnostics, known for its analytical technologies, informatics, and services aimed at advancing scientific breakthroughs.
Why Is Waters (NYSE:WAT) Expanding S&P 500 Diagnostics Focus?
Waters Corporation (NYSE:WAT) is expanding its presence in the diagnostics sector, particularly through at-home HPV screening technology, while maintaining its core business in analytical science and laboratory technology. The company's recent FDA clearance for the Onclarity HPV Self-Collection Kit and approval of the BD Onclarity HPV Assay for at-home use signify a move into clinical diagnostics, complementing its established offerings in liquid chromatography, mass spectrometry, and laboratory automation. Within the S&P 500, Waters represents a healthcare-oriented business that leverages laboratory technology for pharmaceutical research, biotechnology, and clinical diagnostics.
Waters Corporation stock last trades at USD 441.06 on September 28, 2026
Waters Corporation stock closed at USD 441.06 on September 28, 2026, on the New York Stock Exchange, marking a 1.73% increase from its previous close. The company also announced the commercial launch of its BD FACSDiscover A7 Cell Analyzer on September 14, 2026. This information details the stock's performance and a recent product release.
Waters Corp stock gets a USD 515.00 Goldman target
Goldman Sachs has raised its price target for Waters Corp (WAT) to USD 515.00 from USD 465.00, maintaining a Buy rating. This new target is 18.79% above the stock's September 25, 2026 price of USD 433.54, which was near its 52-week high. The target increase follows Waters Corp's strong second-quarter performance, where it exceeded EPS and revenue consensus estimates, reporting EPS of USD 3.05 against a USD 3.01 consensus.
The Bull Case For Waters (WAT) Could Change Following New At-Home HPV And Cell Analysis Push
Waters Corporation's recent partnership with Everlywell for at-home HPV screening and the global launch of its BD FACSDiscover A7 Cell Analyzer are significant moves that could alter its investment narrative. These initiatives deepen Waters' presence in connected diagnostics and high-parameter cell analysis, reinforcing its commitment to a more clinically relevant platform. While these developments align with Waters' diagnostics push, investors should also consider potential integration risks and margin pressures that could impact the company's outlook.
Waters Corp stock trades 0.96 percent below its yearly high of USD 436.34
Waters Corp (WAT) stock is trading at $432.15, just 0.96% below its 52-week high of $436.34. Goldman Sachs recently raised its price target for the company to $515, maintaining a "Buy" rating. Waters Corp reported strong quarterly revenues of $1.65 billion, exceeding analyst expectations.
Waters Corporation stock hits all-time high at 433.09 USD
Waters Corporation (WAT) stock recently hit an all-time high of $433.09, reflecting a nearly 50% increase over the past year. Despite its current P/E ratio of 190.22 indicating potential overvaluation, analysts have revised earnings upwards, and the company reported strong Q2 2026 earnings that surpassed expectations. Recent upgrades by TD Cowen and positive outlooks from Morgan Stanley reinforce investor optimism despite challenges like foreign-exchange pressure and integration of new businesses.
STERIS plc (Ireland) (STE) Stock forecasts
Argus has lowered its target price for STERIS plc (Ireland) (STE) to $230.00. STERIS is a medical technology company specializing in sterilization services and infection prevention. The report was published on September 23, 2026.
Waters Corp stock rises 0.4 percent ahead of the open
Waters Corp stock increased by 0.4 percent to USD 425.78 on September 23, 2026, outperforming the S&P 500, which fell by 0.75 percent. The company's shares reached a new 52-week high of USD 433.09 during the trading session. Upcoming U.S. economic data, including jobless claims and new home sales, are expected to influence the broader market.
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
MaxCyte (MXCT) has appointed Sidharth Kapileshwar as Chief Corporate Development Officer, bringing nearly 25 years of experience in corporate development, strategy, innovation, and M&A from major life sciences companies like Danaher, GE Healthcare, and Beckman Coulter. Kapileshwar's expertise is expected to support MaxCyte's next growth phase, particularly in advancing its flow electroporation technology for cell and gene therapies. His appointment also included inducement awards of stock options and restricted units.
If You Invested $1000 in Agilent Technologies a Decade Ago, This is How Much It'd Be Worth Now
This article examines the investment performance of Agilent Technologies (A) over the past decade. A $1000 investment in Agilent Technologies ten years ago would now be worth $3,583.89, representing a 258.39% gain, outperforming both the S&P 500 and gold over the same period. Analysts are optimistic about Agilent's future, citing sustained instrument demand, pharma exposure, and recent product launches.
Waters Corp stock reaches a 52-week high on September 23
Waters Corp (WAT) stock hit a new 52-week high of $433.09 on September 23, 2026, driven by strong Q2 2026 financial results which saw revenue increase by 113.3% year-over-year to $1.65 billion, surpassing analyst estimates. Despite a demanding market assessment indicated by its P/E ratio, the company provided optimistic Q3 and full-year EPS guidance. The stock's performance highlights investor focus on its operational benchmarks and growth in the laboratory-instrument sector.
Why Did Agilent Technologies (A) Shares Climb After Its Latest Update?
Agilent Technologies (A) recently saw its shares climb after expanding its clinical lab footprint with new CE-IVD-labeled TapeStationDx instruments and software for DNA and RNA quality control in regulated next-generation sequencing workflows. The company has experienced significant share price returns, indicating building momentum. Despite being considered 4% undervalued by a fair value narrative, the article notes potential risks from elevated tariff costs or tightened research funding.
Waters Corp stock gains 2.08 percent ahead of the open
Waters Corp (NYSE: WAT) stock gained 2.08 percent, closing at USD 432.74 on September 22, 2026, outperforming the Nasdaq Composite. The company traded between USD 422.83 and USD 433.06, reaching a new 52-week high. Waters Corp is scheduled to present at the U.S. All Stars Conference on September 23, 2026, at 11:00 a.m. EDT.
Waters Corp stock gains 3.35 percent as revenue recovery matters
Waters Corp stock increased by 3.35 percent over five sessions, closing at USD 423.90 on September 21, 2026. The company, which specializes in analytical instruments for laboratory, pharmaceutical, and industrial testing, saw a 0.56 percent gain in the last session and an 11.44 percent gain year-to-date. Investors are now focused on whether demand for analytical instruments and recurring service activity can sustain the current valuation.
Bruker Corporation (BRKR) stock price, news, quote and history
This article provides a comprehensive overview of Bruker Corporation (BRKR) stock, including its current price, historical data, financial performance, and analyst ratings. It details the company's business segments in medical devices and healthcare, outlining its products and solutions. The information presented also covers key financial metrics, recent news, and performance comparisons against the S&P 500.
Waters Corp stock heads into the open after a 1.9 percent drop
Waters Corp stock closed at USD 421.63 on September 18, 2026, marking a 1.88 percent drop on the NYSE, underperforming the Nasdaq Composite. Goldman Sachs raised its price target for Waters Corp from USD 465 to USD 515, maintaining a buy rating. The company's shares traded between USD 417.20 and USD 429.10 on that day.
Waters Corporation stock hits 52-week high at 427.1 USD
Waters Corporation (WAT) stock achieved a 52-week high of $427.10, showcasing a 38.19% increase over the past year. This milestone follows strong Q2 2026 earnings that surpassed Wall Street expectations, leading to an upgraded rating from TD Cowen and positive analyst sentiment regarding its market position. Despite its strong performance, InvestingPro's Fair Value analysis suggests the stock might currently be overvalued.
Waters Corporation stock hits 52-week high at 427.1 USD By Investing.com
Waters Corporation (WAT) stock reached a new 52-week high of $427.10, reflecting a 38.19% increase over the last year and a 41% six-month return. This milestone follows strong Q2 2026 earnings that exceeded analyst expectations, prompting TD Cowen to upgrade the stock to "Buy" with a $475 price target. Morgan Stanley also noted the company's favorable positioning in the life science diagnostic market due to China's new clinical laboratory service pricing framework.
Waters Launches Spectral Flow Cytometry Analyzer for High-Parameter Research
Waters Corp has launched the BD FACSDiscover A7 Cell Analyzer, expanding its spectral flow cytometry portfolio for academic, pharmaceutical, and contract research organizations. This new analyzer features up to five lasers and 78 detectors, allowing researchers to measure over 50 single-cell characteristics with high reproducibility and standardization. The system aims to make advanced spectral flow cytometry more accessible for applications like biomarker discovery and drug development, building on previous advancements in 50-color flow cytometry.
$1000 Invested In Waters 20 Years Ago Would Be Worth This Much Today
Waters (NYSE: WAT) has significantly outperformed the market over the last 20 years, achieving an average annual return of 11.74%. An initial investment of $1000 in WAT stock two decades ago would now be valued at $9,062.58. This illustrates the substantial impact of compounded returns on investment growth over time.
Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
Waters Corporation has commercially launched the BD FACSDiscover A7 Cell Analyzer, which aims to standardize spectral flow cytometry. This new instrument enables complex 50+ parameter experiments using BD SpectralFX™ Technology and ensures data consistency across instruments and users with FACSTruQ™ Technology. The goal is to accelerate discoveries in immunology and drug development by making advanced flow cytometry more accessible and reliable for researchers.
Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
Waters Corporation has commercially launched the BD FACSDiscover A7 Cell Analyzer, an advanced spectral flow cytometer designed to standardize and accelerate scientific research. This new instrument combines exceptional spectral resolution with industry-leading standardization features like FACSTruQ Technology, enabling researchers to analyze over 50 parameters of a single cell with high reproducibility. It aims to make advanced flow cytometry more accessible, particularly in immunology research and drug development, by improving data consistency across different labs and users.
Waters Corp CEO Udit Batra to speak at J.P. Morgan U.S. All Stars Conference on Sept 23
Waters Corporation announced that CEO Udit Batra will participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference on September 23, 2026. The event will be webcast live and available for replay on the company's investor relations website. This appearance highlights Waters' ongoing engagement with investors and the financial community, underscoring its role as a leader in life sciences and diagnostics.
Waters Corporation to Present at the J.P. Morgan U.S. All Stars Conference
Waters Corporation announced that its President and CEO, Udit Batra, Ph.D., will participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference on September 23, 2026. The event will be webcast live on the company's Investor Relations website, with a replay available for 90 days. Waters Corporation is a global leader in life sciences and diagnostics, focused on analytical technologies and informatics.
UBS assumes coverage on Danaher stock with buy rating, $250 target
UBS has initiated coverage on Danaher Corp. (DHR) with a "buy" rating and a $250 price target, expecting the stock to rise significantly from its current trading price of $205.23. The firm anticipates a return to low single-digit organic growth this year and mid-single digits next year, driven by recovery in bioprocessing, reacceleration in Life Sciences, and improved growth in Diagnostics under the new CEO. Despite recent investor skepticism and downward earnings revisions, UBS believes discrete drivers could support a growth rebound in 2027.
How New Instrument Launches At Thermo Fisher Scientific Stock Have Changed Its Investment Story
Thermo Fisher Scientific recently launched two new instruments, the Multiskan Ease Absorbance Microplate Reader and the EMPAD G2 detector, which expand its offerings in biological assays and advanced materials research. While these product introductions are incremental rather than transformational, they reinforce the company's commitment to refreshing its portfolio and aligning with evolving customer expectations and sustainability programs. Analysts project Thermo Fisher Scientific's revenue to reach US$54.8 billion and earnings to hit US$9.9 billion by 2029, suggesting a 5% upside to its current share price, with an implied P/E multiple compression baked into future forecasts.
Ball Corporation adds two directors to board
Ball Corporation (NYSE:BALL) has appointed Darlene J. Nicosia and Sherry L. Buck to its board of directors, strengthening the board's expertise. Nicosia brings over 30 years of food and beverage industry experience, previously holding leadership roles at The Coca-Cola Company, Inc., while Buck, a former CFO of W. L. Gore & Associates, Inc., adds extensive financial and operating experience. These appointments are expected to bolster the board's capabilities in supporting management.
UBS assumes coverage on Danaher stock with buy rating, $250 target
UBS has initiated coverage on Danaher Corp. (NYSE:DHR) with a buy rating and a $250 price target, expecting organic growth to rebound in the coming years. The positive outlook is attributed to a recovery in bioprocessing, reacceleration in Life Sciences, and improved growth prospects for the Diagnostics division under its new CEO. Despite recent investor skepticism and downward earnings revisions by other analysts, UBS sees discrete drivers for a growth rebound in 2027.
UBS assumes coverage on Danaher stock with buy rating, $250 target
UBS has initiated coverage on Danaher Corp. (NYSE:DHR) with a buy rating and a $250 price target, citing expected organic growth recovery in its bioprocessing, Life Sciences, and Diagnostics segments. The firm anticipates low single-digit growth this year and mid-single-digit growth next year, partly due to strategic capital deployment and the appointment of Julie Sawyer Montgomery as CEO. This outlook comes despite recent investor skepticism and analyst downgrades following a bioprocessing setback.
New CEO took over the reins
Jonathan M. Pratt has taken over as CEO of Qiagen N.V., succeeding Thierry Bernard who led the company for nearly seven years. Pratt brings over 25 years of international leadership experience in the life sciences and healthcare sectors, having previously served in senior roles at Filtration Group, Waters Corporation, and Beckman Coulter Life Sciences. Bernard will assist with the transition until the end of the year.
Research Tools & Consumables Stocks Q2 Highlights: Bruker (NASDAQ:BRKR)
The article reviews the Q2 performance of several research tools and consumables stocks, highlighting Bruker (NASDAQ:BRKR) as having the weakest performance relative to analyst estimates and full-year guidance. In contrast, Avantor (NYSE:AVTR) achieved the best Q2 results with significant analyst estimate beats. Other companies like Waters Corporation (NYSE:WAT), Bio-Techne (NASDAQ:TECH), and Danaher (NYSE:DHR) also had varying Q2 outcomes.
Why Is Waters (NYSE:WAT) Leadership Transition an S&P 500 Story?
Waters Corporation (NYSE:WAT) is undergoing a significant leadership transition, expanding its senior management responsibilities across analytical and material sciences. This move comes after the acquisition of Becton, Dickinson and Company's Biosciences and Diagnostic Solutions business, broadening Waters' operational scope beyond its core analytical instrument activities. The company's performance and strategic shifts remain relevant to the S&P 500, in which it is represented, given its role in the life sciences and diagnostics sector.
Why Is Waters (NYSE:WAT) Gaining S&P 500 Attention After Q2?
Waters Corporation (NYSE:WAT) has garnered S&P 500 attention following a strong second-quarter performance, driven by increased revenue across its laboratory technology businesses. The company specializes in analytical instruments, software, and consumables used in scientific research, pharmaceutical development, and industrial testing. Its operations, distinct from direct healthcare or drug manufacturing, focus on providing tools and technologies to support laboratory activities within pharmaceutical, biotechnology, academic, and industrial sectors globally.
President Rainer Blair Sold A Bunch Of Shares In Danaher
Danaher Corporation's President, Rainer Blair, recently sold a significant portion of his shares, netting US$13 million and reducing his holding by 61%. This insider selling, along with a larger sale by Co-Founder Mitchell Rales for US$130 million, raises some caution, although the sales occurred near current prices. Despite the selling, insiders still own a substantial 11% of the company, valued at US$16 billion, and Danaher continues to be profitable and growing.
This Waters Analyst Turns Bullish; Here Are Top 3 Upgrades For Thursday
This article highlights three significant analyst upgrades for Thursday. Wells Fargo upgraded BWX Technologies (NYSE: BWXT) from Underweight to Equal-Weight, while Piper Sandler upgraded The Macerich Company (NYSE: MAC) from Neutral to Overweight and Waters Corporation (NYSE: WAT) from Neutral to Overweight, boosting Waters' price target to $480. These changes reflect a more bullish outlook from analysts on these companies.
Waters Corporation to Present at the Wells Fargo Healthcare Conference
Waters Corporation announced that its President and Chief Executive Officer, Udit Batra, Ph.D., will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference. The event is scheduled for Wednesday, September 9th, 2026, at 10:15 AM Eastern Time. A live webcast and a 90-day replay will be available on the company's Investor Relations website.
Revvity (RVTY) Draws Heavy Options Interest, Is The Stock Trading At A Premium?
Revvity (RVTY) has seen a surge in options activity, with high implied volatility in its September 2026 $50 put options, indicating expectations for a significant stock movement. The stock has experienced strong recent momentum, but analysts present mixed views on its valuation, with one narrative suggesting it's 3.1% overvalued at $124.84 compared to a fair value of $121.07, while a discounted cash flow model suggests it is undervalued with a fair value of $153.02. Investors are encouraged to review the full picture and various valuation models to form their own thesis.
Waters stock draws new institutional buying as guidance lifts 2026 outlook
Waters Corporation (US9418481035) is attracting new institutional investment as regulatory filings show fresh stakes, and the company issued optimistic 2026 earnings guidance following a significant year-over-year revenue increase. The company reported strong Q3 2026 EPS guidance and full-year guidance that aligns with analyst forecasts, supported by its core business in advanced analytical instruments for life sciences. This positive outlook, combined with new institutional buying and a "Moderate Buy" consensus rating, suggests confidence in Waters' future performance.
How Will Agilent Technologies Stock React To Its Upcoming Earnings?
Agilent Technologies (NYSE:A) is set to report earnings on August 26, 2026. The article analyzes historical post-earnings stock reactions, finding that positive one-day returns occurred 47% of the time over five years, increasing to 64% in the last three years. It also examines correlations between short-term and medium-term post-earnings returns and the influence of peer performance.
Qiagen names Jonathan Pratt as CEO amid takeover talks
Qiagen N.V. announced that Jonathan M. Pratt will become CEO on September 1, 2026, amidst ongoing discussions with potential buyers. Pratt brings over 25 years of experience in life sciences and laboratory technologies, having previously led Filtration Group and held senior roles at Waters Corporation and Beckman Coulter Life Sciences. The appointment follows a comprehensive search, with Pratt succeeding Thierry Bernard while the company continues to evaluate takeover opportunities, including interest from EQT AB and KKR & Co.
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
QIAGEN N.V. announced the appointment of Jonathan M. Pratt as its new Chief Executive Officer, effective September 1, 2026. Pratt brings over 25 years of international leadership experience in life sciences and laboratory technologies, having previously led Filtration Group and held senior roles at Waters Corporation and Beckman Coulter Life Sciences. Thierry Bernard will step down but support the transition, while QIAGEN reaffirms its outlook for Q3 and full-year 2026 and continues its strategic review.
Waters stock holds above $412 as investors digest recent institutional buying
Waters Corporation (WAT) is trading above $412 per share in late August 2026, with institutional investors increasing their positions, indicating confidence in the company's long-term earnings potential. Analysts have a "moderate buy" rating with an average price target of $420.35, suggesting the stock is near its fair value. The company's business model, focusing on analytical instrumentation with recurring revenue from consumables and services, supports a stable outlook for its cash flows and earnings.
Can Revvity (RVTY) Turn Decentralized Prenatal Screening Into a Durable Diagnostics Advantage?
Revvity recently launched SuperFlex, a compact prenatal screening system, aiming to decentralize preeclampsia and biochemical prenatal testing for smaller laboratories and clinics. This move supports Revvity's strategy of combining diagnostics with software, which is crucial for its long-term earnings growth despite potential margin pressures and pricing challenges in markets like China. The article suggests that SuperFlex, alongside software integrations like Signals, could enhance future margins by expanding test menus and consumables use, but investors should remain cautious about reimbursement policy impacts.
